Gossamer bio announces executive management transition and promotion of laura carter, ph.d., to chief scientific officer

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that luisa salter-cid, ph.d., gossamer's chief scientific officer, is resigning from gossamer effective april 30, 2021. on that date, laura carter, ph.d., currently gossamer's senior vice president, research & translational biology
GOSS Ratings Summary
GOSS Quant Ranking